 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE FRA:6ZY told investors it believes it has sufficient cash to fund its operations well into the first half of 2024 after the company reported cash and equivalents of 93.1 million on hand at the end of the first quarter. In a business update for the three months ended March 31, the company reported that cash on hand increased 57 year-over-year from 59.2 million at the end of the first quarter last year. 